Bio-Rad Laboratories Inc.
BIONYSEFree primer · Steps 1–3 of 21Updated May 29, 2026Coverage as of 2026-Q2
Business Model
source: coverage-next-full | ticker: BIO | step: "01" | created: 2026-05-29
Step 01 — Business Overview: Bio-Rad Laboratories Inc. (BIO)
Company Summary
Bio-Rad Laboratories is a global leader in life science research tools and clinical diagnostics, founded in 1952 and headquartered in Hercules, California. The company develops, manufactures, and markets a broad portfolio of products used by researchers, clinicians, and quality control laboratories worldwide. Bio-Rad operates through two segments: Life Science and Clinical Diagnostics, with revenues distributed roughly 40–45% / 55–60% respectively.
Bio-Rad is unique among life science tools companies due to its:
- Schwartz family stewardship — three generations of founding family control via dual-class structure
- Sartorius AG stake — ~12% ownership in Sartorius AG, creating a multi-billion dollar strategic investment
- ddPCR technology leadership — Bio-Rad pioneered and dominates the digital droplet PCR (Droplet Digital PCR, ddPCR) space
Business Segments
Segment 1: Life Science (~40–45% of Revenue)
The Life Science segment serves academic research institutions, pharmaceutical companies, biotechnology companies, government laboratories, and food safety laboratories.
Key Product Lines:
| Product Category | Technology | Use Cases |
|---|---|---|
| Droplet Digital PCR (ddPCR) | QX series instruments + reagent kits | Rare mutation detection, liquid biopsy, gene expression, copy number variation |
| Real-Time PCR (qPCR) | CFX Duet, CFX Opus systems | Gene expression analysis, pathogen detection |
| Gel Electrophoresis / Western Blotting | Trans-Blot Turbo, ChemiDoc systems | Protein analysis, molecular weight determination |
| Cell Imaging & Microscopy | ZOE Fluorescent Cell Imager | Cell biology workflows |
| Protein Interaction / Analysis | GS-900 calibrated densitometer, Bio-Plex multiplex | Protein quantification, cytokine profiling |
| DNA/RNA Purification | Aurum kits | Sample preparation |
| Flow Cytometry | ZE5 Cell Analyzer | Cell sorting, immunophenotyping |
| Chromatography | NGC FPLC systems | Protein purification for bioprocessing/research |
| Food Safety | Genomic-based testing systems | Pathogen detection in food production |
ddPCR Competitive Position:
- Bio-Rad is the originator and dominant player in digital droplet PCR technology
- ddPCR has significant advantages over qPCR for absolute quantification without standards
- Key applications in liquid biopsy (cell-free DNA detection), minimal residual disease (MRD) monitoring, and rare variant detection
- Starplex/Thermo Fisher are attempting competing digital PCR platforms, but Bio-Rad maintains a strong installed base advantage
Life Science Revenue Dynamics:
- Academic/government customers (~40-45% of Life Science revenue) = vulnerable to NIH funding, sequester risk
- Pharma/biotech customers (~50-55%) = high-value, recurring consumables; vulnerable to destocking
- COVID tailwind (2020-2022): ddPCR used extensively for COVID variant detection and diagnostics
- Post-COVID normalization: 2023-2024 saw significant organic revenue decline as biotech/pharma destocked
Segment 2: Clinical Diagnostics (~55–60% of Revenue)
The Clinical Diagnostics segment serves hospital laboratories, blood banks, clinical reference labs, and public health agencies worldwide.
Key Product Lines:
| Product Category | Technology | Use Cases |
|---|---|---|
| Blood Typing / Immunohematology | ID-CARD System (column agglutination) | ABO/Rh typing, antibody screening, crossmatching |
| Serology / Autoimmune | ELISA, multiplex immunoassay | HIV, hepatitis, autoimmune disease testing |
| Quality Controls | Known-value reference materials | Lab QC programs (35,000+ labs globally) |
| Diabetes / Hemoglobin | D-100, D-10 HPLC analyzers | HbA1c testing for diabetes monitoring |
| Specialized Clinical | ELISA, chemiluminescence platforms | Cancer markers, infectious disease |
| Microbiology | Culture and sensitivity testing | Pathogen identification |
Clinical Diagnostics Competitive Position:
- Blood typing: Bio-Rad's ID-CARD (gel-based agglutination) is the #2 global platform behind Ortho Clinical Diagnostics (now QuidelOrtho); strong European position
- Quality controls: Market leader globally — supplies reference materials to 35,000+ clinical labs; high switching costs as labs are accredited around specific QC materials
- Diabetes monitoring: Strong installed base of D-10/D-100 HbA1c analyzers globally
- Clinical Diagnostics is generally more stable than Life Science (hospital budgets vs. research budgets)
Geographic Revenue Mix
| Region | Approximate % of Revenue |
|---|---|
| United States | ~45% |
| Europe | ~35% |
| Asia Pacific & Other | ~20% |
Key geographic observations:
- Strong European presence, particularly in Clinical Diagnostics
- Asia Pacific growing but lower base
- Currency headwinds/tailwinds are meaningful given ~55% international exposure
- China operations subject to geopolitical/procurement risk; has some exposure to Chinese academic and clinical markets
Employees & Operations
- Total employees: ~7,700 globally
- Manufacturing: Multiple facilities in US (Hercules CA, Irvine CA, Redmond WA), Europe (France, Germany), Asia
- R&D headcount: Significant; R&D/Revenue typically 9-12%
- Sales & Marketing: Direct sales force in major markets; distributor network in smaller markets
Sartorius AG Investment
Bio-Rad's ~12% stake in Sartorius AG (Frankfurt: SRT/SRTS) deserves special attention:
- Sartorius AG is a global leader in bioprocess filtration, fermentation, lab instruments (Sartorius Stedim Biotech subsidiary)
- Bio-Rad acquired its stake in 1994 for ~$18M; the investment has compounded massively
- 2021 Peak value: ~$8–9B (when Sartorius AG market cap exceeded €40B)
- 2024 Estimated value: ~$2.5–4B (Sartorius AG declined significantly from bioprocess destocking)
- Bio-Rad marks the stake to fair value each quarter through "Other income (expense)"
- The Sartorius investment provides strategic optionality — could sell to fund acquisitions, buybacks, or special dividends
- Sartorius and Bio-Rad have cross-directorship ties through the Schwartz family
Business Model Summary
Revenue model: ~60%+ of revenues are recurring (reagents, quality controls, consumables tied to installed instrument bases)
Installed base economics:
- Instruments placed at cost or slight loss → decades of reagent revenue
- Switching costs are high once instruments are embedded in lab workflows (software, training, regulatory approval of methods)
- Similar to "razor/blade" dynamic but in professional laboratory context
Margin profile:
- Gross margins: ~55–57% consolidated
- Operating margins: historically 8–14% (compressed by R&D investment and period costs)
- Life Science margins: somewhat higher than Clinical Diagnostics
- Margin compression during 2023-2024 from revenue decline vs. semi-fixed cost base
Key Investment Themes
- Sum-of-parts opportunity: Sartorius stake + operating business potentially worth more separately than current market cap implies
- Destocking recovery: Life Science organic growth should normalize/accelerate in 2025-2026 as biotech/pharma restocks
- ddPCR platform: Leading position in a growing technology with expanding applications (liquid biopsy, oncology, gene therapy QC)
- Margin recovery: As revenues recover, operating leverage should drive meaningful margin expansion
- Family stewardship: Conservative capital allocation, no short-termism, willing to hold Sartorius stake long-term
- Clinical Diagnostics stability: Blood typing / quality controls provide durable recurring revenue floor
Financial Snapshot
source: coverage-next-full | ticker: BIO | step: "04" | created: 2026-05-29
Step 04 — Financial Snapshot: Bio-Rad Laboratories Inc. (BIO)
GAAP P&L Summary (FY2021–FY2024E)
All figures in USD millions except per-share
| Metric | FY2021 | FY2022 | FY2023 | FY2024E |
|---|---|---|---|---|
| Revenue | $3,025 | $2,802 | $2,580 | ~$2,380 |
| Life Science | $1,358 | $1,281 | $1,081 | ~$960 |
| Clinical Diagnostics | $1,667 | $1,521 | $1,499 | ~$1,420 |
| Gross Profit | ~$1,682 | ~$1,539 | ~$1,392 | ~$1,270 |
| Gross Margin | 55.6% | 54.9% | 54.0% | ~53.5% |
| R&D Expense | ~$304 | ~$274 | ~$253 | ~$225 |
| R&D / Revenue | 10.0% | 9.8% | 9.8% | ~9.5% |
| SG&A Expense | ~$804 | ~$719 | ~$666 | ~$610 |
| Operating Income | ~$575 | ~$546 | ~$474 | ~$435 |
| Operating Margin | 19.0% | 19.5% | 18.4% | ~18.3% |
| Adjusted Operating Margin | ~14–17% | ~13–15% | ~10–12% | ~9–11% |
| Interest Income (Expense), net | ~$15 | ~$35 | ~$55 | ~$65 |
| Other income (expense) — Sartorius MTM | +$4,211 | -$4,543 | -$2,100 | ~-$500 to +$500 |
| Pre-tax Income | ~$4,802 | -$3,963 | -$1,571 | ~varies |
| Net Income (GAAP) | ~$3,745 | -$3,246 | -$1,401 | ~varies |
| Diluted EPS (GAAP) | ~$124 | -$108 | -$47 | ~varies |
| Adj. EPS (ex-Sartorius MTM) | ~$15–20 | ~$12–18 | ~$8–12 | ~$7–12 |
Critical Note on Sartorius Mark-to-Market:
- Bio-Rad holds ~37.8M Sartorius AG ordinary shares, accounted for at fair value through P&L
- FY2021: Sartorius AG stock surged ~200%+ → ~$4.2B unrealized gain
- FY2022: Sartorius AG fell ~60%+ → ~$4.5B unrealized loss
- FY2023: Sartorius continued declining → ~$2.1B additional unrealized loss
- These swings make GAAP EPS effectively meaningless for fundamental analysis
- Analysts and investors universally focus on Adjusted EPS (ex-Sartorius MTM)
Segment Financial Performance
Life Science Segment
| Metric | FY2021 | FY2022 | FY2023 | FY2024E |
|---|---|---|---|---|
| Revenue | $1,358M | $1,281M | $1,081M | ~$960M |
| YoY Growth | +18.4% | -5.7% | -15.6% | ~-11% |
| Organic Growth | +15–17% | +4–7% | ~-16% | ~-9 to -12% |
| Segment Op. Income | ~$215M | ~$185M | ~$115M | ~$85M |
| Segment Op. Margin | ~15.8% | ~14.4% | ~10.6% | ~8.8% |
Clinical Diagnostics Segment
| Metric | FY2021 | FY2022 | FY2023 | FY2024E |
|---|---|---|---|---|
| Revenue | $1,667M | $1,521M | $1,499M | ~$1,420M |
| YoY Growth | +8.3% | -8.8% | -1.4% | ~-5% |
| Organic Growth | +5–8% | +0–3% | ~0–2% | ~0–2% |
| Segment Op. Income | ~$360M | ~$361M | ~$358M | ~$350M |
| Segment Op. Margin | ~21.6% | ~23.7% | ~23.9% | ~24.6% |
Note: Segment operating income includes segment-allocated overhead; corporate unallocated costs excluded from segment margins
Key Financial Metrics Timeline
Revenue & Profitability
| Period | Revenue | Op. Margin | Adj. EPS | FCF Margin |
|---|---|---|---|---|
| FY2019 | $2,313M | ~12.5% | ~$8–10 | ~7–9% |
| FY2020 | $2,779M | ~16.5% | ~$12–15 | ~10–12% |
| FY2021 | $3,025M | ~19.0% | ~$15–20 | ~12–14% |
| FY2022 | $2,802M | ~19.5% | ~$12–18 | ~10–12% |
| FY2023 | $2,580M | ~18.4% | ~$8–12 | ~7–10% |
| FY2024E | ~$2,380M | ~18.3% | ~$7–12 | ~6–9% |
Adj. EPS excludes Sartorius MTM, acquisition-related amortization, restructuring charges
Revenue Decline Trajectory
FY2021 Peak: $3,025M
↓ -7.4%
FY2022: $2,802M
↓ -7.9%
FY2023: $2,580M
↓ ~-8%
FY2024E: ~$2,380M
Total revenue decline from FY2021 peak to FY2024E trough: ~-21% Revenue recovery scenario to FY2021 peak: Would require ~+27% growth; likely 4–6 years at normalized growth
Balance Sheet Snapshot
As of most recent reporting (FY2023/Q3 2024 approximate)
| Metric | Value |
|---|---|
| Cash & Equivalents | ~$620–650M |
| Sartorius Stake (Fair Value) | ~$2,500–4,000M (market-dependent) |
| Total Assets | ~$6,500–8,500M (Sartorius-dependent) |
| Total Debt (Long-term) | ~$1,050–1,100M |
| Net Debt (ex-Sartorius) | ~$420–480M |
| Net Debt (inc. Sartorius at FV) | Net cash position by significant margin |
| Total Equity (GAAP) | ~$3,500–5,500M (Sartorius-dependent) |
| Book Value / Share | ~$115–185 (heavily Sartorius-influenced) |
Balance Sheet Interpretation:
- Excluding Sartorius, Bio-Rad has modest net debt (~$400–500M) relative to EBITDA
- Including the Sartorius stake, the company has significant net asset value
- Leverage is manageable; interest coverage remains comfortable even in trough conditions
Per-Share Metrics
| Metric | FY2021 | FY2022 | FY2023 | FY2024E |
|---|---|---|---|---|
| Diluted shares outstanding | ~30.2M | ~30.1M | ~29.9M | ~29.8M |
| GAAP EPS | +$124 | -$108 | -$47 | N/A |
| Adj. EPS (ex-MTM) | ~$17 | ~$14 | ~$10 | ~$8–12 |
| FCF per share | ~$12–16 | ~$10–14 | ~$7–10 | ~$6–9 |
| Book value per share | ~$150+ | ~$55 | ~$65 | ~$85–100 |
Book value per share heavily influenced by Sartorius MTM fair value changes
Important Accounting Notes
1. Sartorius Mark-to-Market Treatment
- Bio-Rad adopted ASU 2016-01 (fair value through P&L for equity investments)
- Sartorius AG ordinary shares marked to market every quarter
- Unrealized gains/losses flow through the "Other income (expense)" line in the income statement
- This is a non-cash item — but it impacts GAAP EPS dramatically
- For analysis purposes, always use Adjusted EPS or Operating Income (ex-Sartorius)
2. Restructuring Charges
- Bio-Rad announced restructuring programs in 2023–2024 targeting ~$60–100M annualized savings
- Restructuring charges (~$50–150M over 2023–2025) are one-time costs but occur regularly
- Targeted headcount reduction and real estate footprint rationalization
3. Amortization of Acquired Intangibles
- Historical acquisitions (RainDance Technologies, etc.) generate amortization
- ~$50–80M annual intangible amortization runs through COGS and operating expenses
- Adjusted metrics typically add back acquisition-related amortization
4. Revenue Recognition
- ASC 606 compliant; instruments recognized at point of delivery
- Reagent/consumable revenue recognized at shipment/delivery
- Service contract revenue recognized ratably over contract term
- No significant multiple-element arrangement complexity
Key Financial Ratios (FY2023, Approximate)
| Ratio | Value | Context |
|---|---|---|
| P/E (GAAP) | N/M (loss year) | Not meaningful due to Sartorius MTM |
| P/E (Adjusted) | ~35–45x | Premium multiple for life science tools |
| EV/EBITDA | ~20–30x | Varies significantly with Sartorius stake backing |
| EV/Revenue | ~3.0–4.5x | Life science tools sector typical |
| Price/Book | ~2–3x | Distorted by Sartorius MTM |
| Gross Margin | 54.0% | Solid for diversified instruments/diagnostics |
| Adj. Operating Margin | ~10–12% | Depressed from FY2021 peak of ~17% |
| Net Debt / EBITDA | ~1.0–1.5x | Ex-Sartorius; manageable |
| FCF Conversion | ~60–75% of net income | Solid capital discipline |
Recent Catalysts
source: coverage-next-full | ticker: BIO | step: "12" | created: 2026-05-29
Step 12 — Catalysts: Bio-Rad Laboratories Inc. (BIO)
Catalyst Framework
Bio-Rad's stock performance is driven by three primary catalyst categories:
- Life Science recovery pace — The most debated near-term driver
- Sartorius stake value — Creates GAAP earnings volatility and sum-of-parts debate
- Margin expansion — Operating leverage story as revenues recover
Near-Term Catalysts (6–12 Months)
Catalyst N1: Life Science Organic Growth Turns Positive
- What: First quarter of positive Life Science organic revenue growth (vs. -10–18% trough)
- When: Most analyst consensus expects Q1–Q2 2025
- Signal importance: Pivotal; market is waiting for evidence that destocking is over
- Price impact: Positive surprise → significant re-rating; likely +10–20% stock upside
- Risk: If recovery delayed to H2 2025 or later → negative re-rating
Catalyst N2: Q4 2024 / FY2025 Guidance
- What: Management's FY2025 revenue and margin guidance at Q4 2024 earnings (~Feb 2025)
- When: February 2025 (estimated)
- Market expectation: ~3–7% organic growth in FY2025; adj. operating margin improvement to 12–14%
- Price impact: Above-consensus guidance = 10–15% upside; below = 10–15% downside
- Key metric to watch: Life Science guidance; Clinical Diagnostics is less contested
Catalyst N3: Restructuring Savings Flowing Through
- What: Full recognition of $60–100M annualized restructuring savings in P&L
- When: FY2025 (primary year of benefit recognition)
- Margin impact: ~250–400 bps adj. operating margin improvement
- Stock impact: Confirms operating leverage thesis; moderate positive
Catalyst N4: Sartorius AG Recovery
- What: Sartorius AG organic growth turning positive; margin recovery; share price re-rating
- When: H2 2024 – H1 2025 (Sartorius recovery expected in 2025)
- Bio-Rad impact: Every €100 increase in Sartorius AG share price = ~$800M increase in Bio-Rad's Sartorius stake value
- GAAP impact: Large positive "Other income" flowing through P&L
- Sum-of-parts impact: Increases Sartorius contribution to Bio-Rad fair value
- Caution: Market may not re-rate Bio-Rad purely on GAAP earnings improvement; focus remains on operating business
Medium-Term Catalysts (1–3 Years)
Catalyst M1: ddPCR Adoption in Liquid Biopsy and Oncology
- What: Broader FDA clearance and clinical adoption of ddPCR for MRD (minimal residual disease) monitoring in cancer
- Timeline: 2025–2027
- Market size: Liquid biopsy TAM $3–8B by 2030; ddPCR could capture $500M–1B
- Stock impact: Significant if Bio-Rad establishes a dominant clinical ddPCR position
- Risk: Illumina/Foundation Medicine / Guardant Health use NGS platforms; ddPCR competes in specific niches only
Catalyst M2: Gene Therapy QC Market Maturation
- What: Gene therapy market expanding → ddPCR demand for viral vector characterization (AAV, lentiviral)
- Timeline: 2025–2030
- Bio-Rad position: ddPCR is the preferred method for viral genome titer quantification (regulatory standard)
- Market impact: Every $1B in gene therapy product revenue generates ~$15–25M in ddPCR consumable demand
- Stock impact: Structural demand driver; modestly positive incremental revenue
Catalyst M3: Sartorius Partial Monetization / Capital Return
- What: Bio-Rad sells 5–15% of Sartorius stake and deploys proceeds for buyback or special dividend
- Timeline: 1–3 years (possible but not certain)
- Stake value at 15% trim: ~$420–480M proceeds (at base case Sartorius price) → ~$350–380M net of taxes
- Per-share impact: Could fund buyback of ~1.2–1.5M shares (4–5% of float) → meaningful accretive
- Stock re-rating: Sum-of-parts discount could narrow by 10–15% upon partial monetization
- Probability: ~20–30% over next 2 years
Catalyst M4: Operating Margin Recovery to 14–16%
- What: As revenues recover toward $2.8–3.0B, operating leverage drives margin recovery
- Timeline: FY2026–2027
- Margin trajectory: 9–10% (2024) → 12–14% (2025) → 14–16% (2026–2027)
- EPS impact: At $3.0B revenue and 15% op. margin = ~$450M op. income → ~$350M net income → ~$11–13 adj. EPS
- Valuation impact: At 30x adj. P/E = $330–390 stock price; meaningful upside vs. current ~$280–320
Long-Term Catalysts (3–5+ Years)
Catalyst L1: Sum-of-Parts Recognition
- What: Market gives Bio-Rad full credit for Sartorius stake + operating business value
- Scenario: Sartorius stake at $3B net of tax ($100/share) + operating business at 20x EV/EBITDA = $200–250/share → total fair value $300–350+
- Current discount: Market appears to apply ~20–30% holding company discount to Sartorius stake
- Catalyst: Activist investor pressure, partial sale, or simply Sartorius recovery narrowing the gap
Catalyst L2: M&A Takeout / Strategic Combination
- What: Larger life science company (Thermo, Danaher, Abbott) acquires Bio-Rad or its operating assets
- Probability: Low — Schwartz family dual-class control makes hostile takeover impossible; family unlikely to sell
- Premium if it happened: 30–50% premium to current price
- Optionality value: Provides a floor on valuation for sum-of-parts investors
Reverse Catalysts (Downside)
Reverse Catalyst R1: Life Science Recovery Stalls
- Organic growth remains negative through FY2025
- Drivers: NIH budget cuts, prolonged biotech funding weakness, China market deterioration
- Downside impact: -20–30% from current price
Reverse Catalyst R2: Sartorius AG Continues Declining
- Sartorius AG business fundamentals deteriorate further; share price falls to €100–120
- Bio-Rad stake value: ~$1.5–1.8B (vs. ~$2.8–3.2B today)
- GAAP impact: Additional multi-billion dollar reported losses
- Sum-of-parts impact: Reduces Bio-Rad fair value by ~$35–50/share
Reverse Catalyst R3: NIH Budget Cuts Materialize
- DOGE-related NIH budget cuts of 20–30% flow through to academic lab spending in FY2025–2026
- Life Science recovery pushed back; margins compressed longer
- Revenue impact: -$80–150M incremental headwind
Bull Case
- Life Science organic growth returns to 5–8% by mid-2025, confirming destocking is complete and driving significant earnings upgrade cycle with operating leverage
- Sartorius AG shares recover 50–70% as bioprocess market normalizes, adding $1–1.5B in stake value and triggering sum-of-parts re-rating of Bio-Rad
- Bio-Rad monetizes 10% of Sartorius stake at recovered prices, funding a $300–400M buyback that reduces shares outstanding by 4–5% and narrows the holding company discount
Bear Case
- NIH budget cuts of 20–25% extend Life Science revenue declines through FY2025, pushing adj. operating margin below 8% and triggering further consensus earnings cuts
- Sartorius AG recovery disappoints and shares decline to €100–120, reducing Bio-Rad's stake value to ~$1.5–1.8B and creating another year of multi-billion dollar GAAP losses that drive retail investor selling
- ddPCR competitive pressure intensifies as key patents expire 2025–2027, with Thermo Fisher aggressively pricing competing digital PCR systems to displace Bio-Rad in new lab placements
Full Research Available
This primer covers steps 1–3 of 21. The full deep dive includes moat analysis, DCF valuation, bull/bear scenarios, management quality, earnings transcript analysis, competitive positioning, returns on capital, institutional/insider activity, and an investment memo.
View Investment MemoEach memo is $2. Coverage subscriptions for funds coming soon — join the waitlist.